BaroFold Grants Protein Technology Research License to Genentech
Complete the form below to unlock access to ALL audio articles.
BaroFold, Inc. has announced the granting of a research license to Genentech, Inc. for BaroFold's proprietary PreEMT™ high pressure technology for solubilizing, disaggregating and refolding proteins under a previously executed service and license agreement.
The license agreement enables Genentech to utilize BaroFold's patented technology and instrumentation for research, and grants Genentech an option to trigger a commercial license.
Genentech joins several other biotechnology firms and pharmaceutical corporations who have collaborated with BaroFold to refold and produce proteins.
"We are pleased to be working with Genentech, a leader and pioneer in the field of therapeutic proteins," said Lyndal Hesterberg, President and CEO of BaroFold Inc.
"Our team has now delivered useful quantities of over 80 challenging proteins through its collaborations with academics and biologics industry scientists."
"We hope to support future development of important therapeutic biologics programs at Genentech."
